Biophysical and Lipidomic Biomarkers of Cardiac Remodeling Post-Myocardial Infarction in Humans.

Fourier transform infrared spectroscopy biophysical markers cardiac remodeling post-MI heart failure lipidomics

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
22 10 2020
Historique:
received: 16 09 2020
revised: 14 10 2020
accepted: 21 10 2020
entrez: 27 10 2020
pubmed: 28 10 2020
medline: 7 9 2021
Statut: epublish

Résumé

Few studies have analyzed the potential of biophysical parameters as markers of cardiac remodeling post-myocardial infarction (MI), particularly in human hearts. Fourier transform infrared spectroscopy (FTIR) illustrates the overall changes in proteins, nucleic acids and lipids in a single signature. The aim of this work was to define the FTIR and lipidomic pattern for human left ventricular remodeling post-MI. A total of nine explanted hearts from ischemic cardiomyopathy patients were collected. Samples from the right ventricle (RV), left ventricle (LV) and infarcted left ventricle (LV INF) were subjected to biophysical (FTIR and differential scanning calorimetry, DSC) and lipidomic (liquid chromatography-high-resolution mass spectrometry, LC-HRMS) studies. FTIR evidenced deep alterations in the myofibers, extracellular matrix proteins, and the hydric response of the LV INF compared to the RV or LV from the same subject. The lipid and esterified lipid FTIR bands were enhanced in LV INF, and both lipid indicators were tightly and positively correlated with remodeling markers such as collagen, lactate, polysaccharides, and glycogen in these samples. Lipidomic analysis revealed an increase in several species of sphingomyelin (SM), hexosylceramide (HexCer), and cholesteryl esters combined with a decrease in glycerophospholipids in the infarcted tissue. Our results validate FTIR indicators and several species of lipids as useful markers of left ventricular remodeling post-MI in humans.

Identifiants

pubmed: 33105904
pii: biom10111471
doi: 10.3390/biom10111471
pmc: PMC7690619
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : FIS PI18/01584
Organisme : Instituto de Salud Carlos III
ID : FIS PI20/01702
Organisme : Fundació Marató TV3
ID : 201516_10

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Am Coll Cardiol. 2008 Jul 8;52(2):117-23
pubmed: 18598890
Forensic Sci Int. 2011 Apr 15;207(1-3):e34-9
pubmed: 21216544
Eur J Nutr. 2013 Mar;52(2):749-58
pubmed: 22645107
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
J Biol Chem. 1991 Mar 25;266(9):5629-33
pubmed: 2005103
Circulation. 2020 Mar 17;141(11):916-930
pubmed: 31992066
Rapid Commun Mass Spectrom. 2010 Jul 30;24(14):2057-64
pubmed: 20552694
Analyst. 2010 Dec;135(12):3110-9
pubmed: 20967384
Lancet. 2006 Jan 28;367(9507):356-67
pubmed: 16443044
Cardiovasc Hematol Disord Drug Targets. 2018;18(3):166-175
pubmed: 29683098
FASEB J. 2020 Jul 15;:
pubmed: 32666604
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1500-1509
pubmed: 28245984
Sci Rep. 2018 Mar 20;8(1):4919
pubmed: 29559686
PLoS One. 2013 Apr 26;8(4):e61942
pubmed: 23637933
Anal Bioanal Chem. 2006 Dec;386(7-8):1961-6
pubmed: 17043797
Eur Heart J. 2016 Jul 01;37(25):1967-76
pubmed: 27125947
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1411-20
pubmed: 21454812
PLoS One. 2011;6(6):e20411
pubmed: 21687659
Basic Res Cardiol. 2001 May-Jun;96(3):267-74
pubmed: 11403420
Biochim Biophys Acta. 2016 Jan;1864(1):85-101
pubmed: 26327318
Chem Soc Rev. 2016 Apr 7;45(7):1980-98
pubmed: 26403652
Lipids. 2018 Feb;53(2):177-187
pubmed: 29394450
J Mol Cell Cardiol. 2013 Feb;55:12-8
pubmed: 22982115
Circulation. 2018 Jul 17;138(3):305-315
pubmed: 30012703
J Clin Invest. 1991 Jul;88(1):331-5
pubmed: 2056126
Cardiovasc Res. 2012 Jun 1;94(3):469-79
pubmed: 22454363
J Transl Med. 2012 Aug 08;10:160
pubmed: 22873206
Int J Cardiol. 2017 Jan 15;227:239-246
pubmed: 27852445
Eur Heart J. 2005 Jun;26(11):1115-40
pubmed: 15901669
J Physiol Pharmacol. 2002 Sep;53(3):371-82
pubmed: 12369735
J Agric Food Chem. 2004 Jun 16;52(12):3920-9
pubmed: 15186118
J Mol Cell Cardiol. 2011 Apr;50(4):598-605
pubmed: 21262230
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jan 24;118:981-6
pubmed: 24161861
Anal Biochem. 2003 May 15;316(2):232-42
pubmed: 12711345
Ann Biomed Eng. 2012 Sep;40(9):2069-77
pubmed: 22419197
Radiology. 2009 Oct;253(1):65-73
pubmed: 19703860
J Extracell Vesicles. 2016 Jul 05;5:30741
pubmed: 27389011
Circulation. 1990 Apr;81(4):1161-72
pubmed: 2138525
Biochim Biophys Acta. 2016 Jan;1857(1):34-45
pubmed: 26482708
Anal Bioanal Chem. 2009 Oct;395(3):829-37
pubmed: 19685340
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185661
J Mol Cell Cardiol. 2011 May;50(5):894-902
pubmed: 21338608
Am J Pathol. 1997 Nov;151(5):1257-63
pubmed: 9358751
Acta Biochim Biophys Sin (Shanghai). 2007 Aug;39(8):549-59
pubmed: 17687489
Int J Biochem Cell Biol. 2014 Oct;55:209-19
pubmed: 25218173
Circulation. 2003 Sep 16;108(11):1395-403
pubmed: 12975244
Eur J Epidemiol. 2018 Jan;33(1):55-66
pubmed: 29181692
J Biomed Opt. 2012 May;17(5):056014
pubmed: 22612137
J Clin Invest. 2018 Jul 2;128(7):2702-2712
pubmed: 30108193
Cardiovasc Res. 2001 Dec;52(3):407-16
pubmed: 11738057
J Thorac Cardiovasc Surg. 2010 Nov;140(5):1160-7
pubmed: 20850803
J Cell Mol Med. 2018 Sep;22(9):4197-4208
pubmed: 29921039
J Cell Sci. 2017 Jan 15;130(2):315-324
pubmed: 28049719
Med Sci Monit. 2018 Jun 18;24:4175-4182
pubmed: 29913478

Auteurs

Valerie Samouillan (V)

CIRIMAT, Université de Toulouse, Université Paul Sabatier, Equipe PHYPOL, 31062 Toulouse, France.

Ignacio Miguel Martinez de Lejarza Samper (IM)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

Aleyda Benitez Amaro (AB)

Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain.
Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

David Vilades (D)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

Jany Dandurand (J)

CIRIMAT, Université de Toulouse, Université Paul Sabatier, Equipe PHYPOL, 31062 Toulouse, France.

Josefina Casas (J)

Research Unit on BioActive Molecules (RUBAM), Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain.
CIBEREHD Institute of Health Carlos III, 28029 Madrid, Spain.

Esther Jorge (E)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

David de Gonzalo Calvo (D)

Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain.
Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Alberto Gallardo (A)

Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Enrique Lerma (E)

Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Jose Maria Guerra Ramos (JMG)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

Francesc Carreras (F)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

Ruben Leta (R)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.

Vicenta Llorente Cortes (V)

CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain.
Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain.
Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH